Clinical Trial Update: A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) [Phase 2]

View source ↗

Summary

Phase 2 trial of tabalumab in previously treated multiple myeloma completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tabalumab (tabalumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-08-15